MNTA: "I really can't say it's a steal because of what we don't know."
{Why did you re-buy at $18 then? What don't "we" know?}
"I believe the selloff was largely caused by Momenta's claim that it had to reimburse Sandoz x dollars."
{I guess everyone knew about the reimbursement but you? This is a simplistic assessment of the share depression}
"While we don't know how much money this is, it is somewhat comforting that it will be paid for over the next couple of quarters."
{We do know how much. If it is "comforting" to you than why should it be an issue?}
"This liability really put into question (in my view) whether Momenta will have to go back to the capital markets. I think Momenta has around $63 in current assets, if this unknown liability were to be put on the balance sheet, it could look ugly."
{The "unknown liability" amounts are deducted from royalties from Sandoz up to 50% of cash flow. You are ignoring the obvious facts, imo}
"The more I watch this, the more I think that Sandoz is the real financial winner in regards to generic lovenox."
{Perhaps you should've invested in NVS, rather than MNTA? MNTA's share price appreciation has been substantially greater than NVS's post-approval, thus, your last point is moot. This is a drop in the revenue bucket for Sandoz/NVS compared to MNTA}
Market Data 
Markets 
AI
